Thieler Law Corp advises investors with losses exceeding $100,000 of the June 18, 2021lead plaintiff deadline in a class action lawsuit filed against  Emergent BioSolutions Inc. (NYSE: EBS) ( Emergent BioSolutions Inc. or “the Company”). The suit is pending in the U.S. District Court for the District of Maryland and investors, who purchased  Emergent BioSolutions Inc. securities between April 24, 2020 through April 16, 2021, have until June 18, 2021 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased  Emergent BioSolutions Inc. securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

Emergent is a specialty biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases. In response to the novel strain of coronavirus (SARS-CoV-2) causing COVID-19 disease (“COVID-19”) pandemic, Emergent signed a series of deals with Johnson & Johnson (“J&J”) and AstraZeneca worth a combined $876 million to provide contract development and manufacturing organization (“CDMO”) services to produce the companies’ COVID-19 vaccine candidates. Emergent received a further $628 million from the U.S. government as a part of the Warp Speed Program, for a total of over $1.5 billion in COVID-19 deals.

On April 23, 2020, the Company first announced that it had entered into an agreement with J&J to be the U.S. manufacturing partner for J&J’s COVID-19 vaccine candidate based out of Emergent’s manufacturing facility in the Bayview neighborhood of Baltimore, Maryland. At the time of this initial announcement, Defendants touted its Baltimore facility’s “unique capabilities across four independent suites to produce at clinical scale to get candidates rapidly into the clinic, while at the same time scaling up to enable large-scale manufacturing . . . to prepare for production of commercial volumes to meet customer demand.”

On March 31, 2021, when media reports revealed that employees at Emergent’s Baltimore facility had “mixed up” ingredients for the J&J and AstraZeneca vaccines, contaminating up to 15 million doses of the J&J vaccine. Reports further indicated that the Food and Drug Administration (“FDA”) had “repeatedly . . . cited Emergent for problems such as poorly trained employees, cracked vials and problems managing mold and other contamination around one of its facilities.” Further, it was revealed that an April 2020 FDA inspection of Emergent’s Baltimore facility had uncovered “a series of quality control shortcomings” including, among other things, the “fail[ure] to ensure that electronic data generated through testing of drug ingredients ‘was protected from deletion or manipulation,”’ the failure to “follow proper testing and lab procedures,” and “carelessness in the handling of rejected materials in the [Baltimore] Bayview plant.”

According to the lawsuits, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Emergent's Baltimore facility had a history of manufacturing issues increasing the likelihood for massive contaminations; (2) the Baltimore facility had received a series of FDA citations as a result of these contamination risks and quality control issues; (3) Emergent had been forced to discard millions of doses of COVID-19 vaccines after workers at the facility deviated from manufacturing standards; and (4) as a result of the foregoing, the defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore facility were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you were negatively impacted by your investment in  Emergent BioSolutions Inc. (NYSE: EBS) securities between April 24, 2020 through April 16, 2021 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185